April 14, 2021-April 15, 2021 View Now: 12th Annual Patient-Reported Outcome Consortium Workshop – Held Virtually April 14–15, 2021 On April 14–15, 2021, the 12th Annual Patient-Reported Outcome Consortium Workshop was held in a virtual f
April 14, 2021-April 15, 2021 Identifying COAs for Use in Rare Disease Treatment Trials Presented at the PRO Consortium 2021 Workshop, held virtually April 14-15, 2021:
April 14, 2021 CPTA Welcomes Triplet Therapeutics Chief Medical Officer as Industry Co-Director C-Path’s Critical Path to Therapeutics for the Ataxias Consortium is pleased to announce the appointment of Irina Antonijevi
April 12, 2021 C-Path’s Alzheimer’s Disease Consortium Expands Data Repository New patient-level data will facilitate more efficient clinical trial design TUCSON, Ariz., April 12, 2021 — The Critical Path In
April 8, 2021 CP-SCD Announces Pfizer Executive as its First Industry Co-Director C-Path’s Critical Path to Sickle Cell Disease Consortium (CP-SCD) is pleased to announce Dr. David Readett of Pfizer as its firs
April 7, 2021 Standardized Data Structures in Rare Diseases: CDISC User Guides for Duchenne Muscular Dystrophy and Huntington’s Disease Interest in drug development for rare diseases has expanded dramatically since the Orphan Drug Act was passed in 1983,
April 7, 2021 FAIR data sharing: The roles of common data elements and harmonization. Journal of Biomedical Informatics. 2020 July D. Kush, D. Warzel, M.A. Kush, A. Sherman, E.A. Navarro, R. Fitzmartin, F. Pétavy, J. Galvez, L.B. Becnel, F.L. Zhou, N. Harmon..
April 7, 2021 Development of a regulatory-ready clinical trial simulation tool for Duchenne muscular dystrophy Abstract WMS 2020
April 7, 2021 Development of a regulatory-ready clinical trial simulation tool for Duchenne muscular dystrophy poster WMS 2020
April 7, 2021 Development of Clinical Trial Simulation Tool for Duchenne Muscular Dystrophy Through the Duchenne Regulatory Science Abstract WMS 2019
